Cargando…
Intestinal Dysbiosis and Autoimmune Pancreatitis
Autoimmune pancreatitis (AIP) is a chronic fibro-inflammatory disorder of the pancreas. Recent clinicopathological analysis revealed that most cases of AIP are pancreatic manifestations of systemic IgG4-related disease (IgG4-RD), a newly established disease characterized by enhanced IgG4 antibody re...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021793/ https://www.ncbi.nlm.nih.gov/pubmed/33833754 http://dx.doi.org/10.3389/fimmu.2021.621532 |
_version_ | 1783674807391354880 |
---|---|
author | Yoshikawa, Tomoe Watanabe, Tomohiro Kamata, Ken Hara, Akane Minaga, Kosuke Kudo, Masatoshi |
author_facet | Yoshikawa, Tomoe Watanabe, Tomohiro Kamata, Ken Hara, Akane Minaga, Kosuke Kudo, Masatoshi |
author_sort | Yoshikawa, Tomoe |
collection | PubMed |
description | Autoimmune pancreatitis (AIP) is a chronic fibro-inflammatory disorder of the pancreas. Recent clinicopathological analysis revealed that most cases of AIP are pancreatic manifestations of systemic IgG4-related disease (IgG4-RD), a newly established disease characterized by enhanced IgG4 antibody responses and the involvement of multiple organs. Although the immuno-pathogenesis of AIP and IgG4-RD has been poorly defined, we recently showed that activation of plasmacytoid dendritic cells (pDCs) with the ability to produce large amounts of IFN-α and IL-33 mediates chronic fibro-inflammatory responses in experimental and human AIP. Moreover, M2 macrophages producing a large amount of IL-33 play pathogenic roles in the development of human IgG4-RD. Interestingly, recent studies including ours provide evidence that compositional alterations of gut microbiota are associated with the development of human AIP and IgG4-RD. In addition, intestinal dysbiosis plays pathological roles in the development of chronic pancreatic inflammation as dysbiosis mediates the activation of pDCs producing IFN-α and IL-33, thereby causing experimental AIP. In this Mini Review, we focus on compositional alterations of gut microbiota in AIP and IgG4-RD to clarify the mechanisms by which intestinal dysbiosis contributes to the development of these disorders. |
format | Online Article Text |
id | pubmed-8021793 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80217932021-04-07 Intestinal Dysbiosis and Autoimmune Pancreatitis Yoshikawa, Tomoe Watanabe, Tomohiro Kamata, Ken Hara, Akane Minaga, Kosuke Kudo, Masatoshi Front Immunol Immunology Autoimmune pancreatitis (AIP) is a chronic fibro-inflammatory disorder of the pancreas. Recent clinicopathological analysis revealed that most cases of AIP are pancreatic manifestations of systemic IgG4-related disease (IgG4-RD), a newly established disease characterized by enhanced IgG4 antibody responses and the involvement of multiple organs. Although the immuno-pathogenesis of AIP and IgG4-RD has been poorly defined, we recently showed that activation of plasmacytoid dendritic cells (pDCs) with the ability to produce large amounts of IFN-α and IL-33 mediates chronic fibro-inflammatory responses in experimental and human AIP. Moreover, M2 macrophages producing a large amount of IL-33 play pathogenic roles in the development of human IgG4-RD. Interestingly, recent studies including ours provide evidence that compositional alterations of gut microbiota are associated with the development of human AIP and IgG4-RD. In addition, intestinal dysbiosis plays pathological roles in the development of chronic pancreatic inflammation as dysbiosis mediates the activation of pDCs producing IFN-α and IL-33, thereby causing experimental AIP. In this Mini Review, we focus on compositional alterations of gut microbiota in AIP and IgG4-RD to clarify the mechanisms by which intestinal dysbiosis contributes to the development of these disorders. Frontiers Media S.A. 2021-03-23 /pmc/articles/PMC8021793/ /pubmed/33833754 http://dx.doi.org/10.3389/fimmu.2021.621532 Text en Copyright © 2021 Yoshikawa, Watanabe, Kamata, Hara, Minaga and Kudo http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Yoshikawa, Tomoe Watanabe, Tomohiro Kamata, Ken Hara, Akane Minaga, Kosuke Kudo, Masatoshi Intestinal Dysbiosis and Autoimmune Pancreatitis |
title | Intestinal Dysbiosis and Autoimmune Pancreatitis |
title_full | Intestinal Dysbiosis and Autoimmune Pancreatitis |
title_fullStr | Intestinal Dysbiosis and Autoimmune Pancreatitis |
title_full_unstemmed | Intestinal Dysbiosis and Autoimmune Pancreatitis |
title_short | Intestinal Dysbiosis and Autoimmune Pancreatitis |
title_sort | intestinal dysbiosis and autoimmune pancreatitis |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021793/ https://www.ncbi.nlm.nih.gov/pubmed/33833754 http://dx.doi.org/10.3389/fimmu.2021.621532 |
work_keys_str_mv | AT yoshikawatomoe intestinaldysbiosisandautoimmunepancreatitis AT watanabetomohiro intestinaldysbiosisandautoimmunepancreatitis AT kamataken intestinaldysbiosisandautoimmunepancreatitis AT haraakane intestinaldysbiosisandautoimmunepancreatitis AT minagakosuke intestinaldysbiosisandautoimmunepancreatitis AT kudomasatoshi intestinaldysbiosisandautoimmunepancreatitis |